Taken together, our observation indicated that LINC02568 serves as a potential therapeutic target in ER+ breast cancer, such that ASO targeting LINC02568 alone or in combination with endocrine therapy drugs or CA12 inhibitor is potent in inhibiting ER+ breast tumor growth. This evidence concerns the gene ESR1 and breast carcinoma.